Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis.
Patient-reported outcome
Psychometrics
Symptom severity
Ulcerative colitis
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
06
10
2022
accepted:
19
12
2022
medline:
18
5
2023
pubmed:
12
2
2023
entrez:
11
2
2023
Statut:
ppublish
Résumé
Due to wide-ranging impacts of Ulcerative Colitis (UC), regulatory authorities emphasize the importance of including validated patient-reported symptom severity measures in clinical trials. To describe the development and validation of the Ulcerative Colitis-Symptom Questionnaire (UC-SQ). The UC-SQ was developed in a qualitative study involving a targeted literature review, semi-structured concept elicitation interviews, and combined concept elicitation/cognitive interviews. Measurement properties, including item-level analyses, factor structure, reliability, validity, responsiveness, and clinically meaningful change were evaluated using data from a phase 2b, randomized trial in adults with UC (N = 113). Fourteen symptom concepts were elicited across 22 interviews, with saturation at the fifth interview. Twenty-two items were unmodified as cognitive interview participants interpreted underlying concepts correctly. Instructions were clear and items were relevant, with appropriate response options and recall periods. Reduction to 17 items was completed prior to psychometric testing. Two items (joint pain/constipation) did not contribute to reliability in initial testing and were included as non-scored items. The 15-item UC-SQ showed evidence of internal consistency (α = 0.86) and test-retest reliability (intraclass correlation coefficient = 0.88). The UC-SQ discriminated by disease severity as defined by Mayo and Inflammatory Bowel Disease Questionnaire scores (p < 0.0001). Convergent validity was supported by strong correlations with criterion measures. The UC-SQ was responsive in patients indicating change in other measures. A 10-point decrease from baseline indicated within-patient meaningful improvement. The UC-SQ is reliable, valid and responsive, with a 10-point improvement estimating within-patient clinically meaningful improvement. The tool is fit-for-purpose as a key endpoint in pivotal UC trials.
Sections du résumé
BACKGROUND
Due to wide-ranging impacts of Ulcerative Colitis (UC), regulatory authorities emphasize the importance of including validated patient-reported symptom severity measures in clinical trials.
AIM
To describe the development and validation of the Ulcerative Colitis-Symptom Questionnaire (UC-SQ).
METHODS
The UC-SQ was developed in a qualitative study involving a targeted literature review, semi-structured concept elicitation interviews, and combined concept elicitation/cognitive interviews. Measurement properties, including item-level analyses, factor structure, reliability, validity, responsiveness, and clinically meaningful change were evaluated using data from a phase 2b, randomized trial in adults with UC (N = 113).
RESULTS
Fourteen symptom concepts were elicited across 22 interviews, with saturation at the fifth interview. Twenty-two items were unmodified as cognitive interview participants interpreted underlying concepts correctly. Instructions were clear and items were relevant, with appropriate response options and recall periods. Reduction to 17 items was completed prior to psychometric testing. Two items (joint pain/constipation) did not contribute to reliability in initial testing and were included as non-scored items. The 15-item UC-SQ showed evidence of internal consistency (α = 0.86) and test-retest reliability (intraclass correlation coefficient = 0.88). The UC-SQ discriminated by disease severity as defined by Mayo and Inflammatory Bowel Disease Questionnaire scores (p < 0.0001). Convergent validity was supported by strong correlations with criterion measures. The UC-SQ was responsive in patients indicating change in other measures. A 10-point decrease from baseline indicated within-patient meaningful improvement.
CONCLUSIONS
The UC-SQ is reliable, valid and responsive, with a 10-point improvement estimating within-patient clinically meaningful improvement. The tool is fit-for-purpose as a key endpoint in pivotal UC trials.
Identifiants
pubmed: 36773193
doi: 10.1007/s10620-022-07807-y
pii: 10.1007/s10620-022-07807-y
pmc: PMC10188579
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2318-2332Informations de copyright
© 2023. The Author(s).
Références
Ye Y, Manne S, Treem WR, Bennett D. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007–2016. Inflamm Bowel Dis. 2020;26:619–625.
pubmed: 31504515
Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778.
doi: 10.1016/S0140-6736(17)32448-0
pubmed: 29050646
Gajendran M, Loganathan P, Jimenez G et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851.
doi: 10.1016/j.disamonth.2019.02.004
pubmed: 30837080
Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context. 2019;8:212572.
doi: 10.7573/dic.212572
pubmed: 31065290
pmcid: 6490072
Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.
doi: 10.1016/j.cgh.2006.09.033
pubmed: 17142106
US Food and Drug Administration. Ulcerative colitis: clinical trial endpoints guidance for industry. 2016.
Reinisch W, Gottlieb K, Colombel JF et al. Comparison of the EMA and FDA guidelines on ulcerative colitis drug development. Clin Gastroenterol Hepatol. 2019;17:1673–1679.
doi: 10.1016/j.cgh.2018.10.032
pubmed: 31352970
US Food and Drug Administration. Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation. 2020.
US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009.
European Medicines Agency. Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis. In: (CHMP) CfMPfHU, ed. CHMP/EWP/18463/2006 Rev.1 ed 2018.
European Medicines Agency. Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. 2005.
Joffe H, Yardley L. Content and thematic analysis. In: Marks DF, Yardley L, eds. Research methods for clinical and health psychology, vol56. Thousand Oaks: SAGE Publications; 2004; 68.
Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10:269–281.
doi: 10.1586/erp.10.30
pubmed: 20545592
Lim CR, Harris K, Dawson J, Beard DJ, Fitzpatrick R, Price AJ. Floor and ceiling effects in the OHS: an analysis of the NHS PROMs data set. BMJ Open. 2015;5:e007765.
doi: 10.1136/bmjopen-2015-007765
pubmed: 26216152
pmcid: 4521553
Nunnally JC. Psychometric theory, 2nd edn. New York: McGraw-Hill; 1978.
Nunnally JC. Psychometric theory 3E. New York: Tata McGraw-Hill Education; 1994.
Stevens SS. Handbook of experimental psychology. New York: Wiley; 1951.
Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155–163.
doi: 10.1016/j.jcm.2016.02.012
pubmed: 27330520
pmcid: 4913118
McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30.
doi: 10.1037/1082-989X.1.1.30
Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–428.
doi: 10.1037/0033-2909.86.2.420
pubmed: 18839484
Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: the example of health-related quality of life—a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J. 2002;36:209–238.
doi: 10.1177/009286150203600127
Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: Lawrence Erlbaum Associates, Publishers; 1988.
da Silva BC, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20:9458–9467.
doi: 10.3748/wjg.v20.i28.9458
pubmed: 25071340
pmcid: 4110577
Joyce JC, Waljee AK, Khan T et al. Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity. Health Qual Life Outcomes. 2008;6:69.
doi: 10.1186/1477-7525-6-69
pubmed: 18803870
pmcid: 2559827
Lynch WD, Hsu R. Ulcerative Colitis. In: StatPearls. Treasure Island: StatPearls Publishing; 2021.
Maunder RG, Greenberg GR. Comparison of a disease activity index and patients’ self-reported symptom severity in ulcerative colitis. Inflamm Bowel Dis. 2004;10:632–636.
doi: 10.1097/00054725-200409000-00020
pubmed: 15472526
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756–1770.
doi: 10.1016/S0140-6736(16)32126-2
pubmed: 27914657
Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD. Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. Eur J Gastroenterol Hepatol. 2009;21:558–564.
doi: 10.1097/MEG.0b013e328326cacb
pubmed: 19194304
pmcid: 3193174
Higgins PDR, Harding G, Revicki DA et al. Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary. J Patient Rep Outcomes. 2017;2:26.
doi: 10.1186/s41687-018-0049-2
pubmed: 29888745